Skip to main content

Greenberg Traurig Advises a Chinese Pharmaceutical Company

WARSAW – Sept. 29, 2015 – Greenberg Traurig represented Brokton Investments, a company controlled by Mr. Zhu Jiman, in its acquisition of a significant block of shares in Bioton S.A. on a regulated market. As a result of the acquisition of the shares in Bioton S.A., representatives of Brokton Investments have been appointed to the Supervisory Board of Bioton S.A. The capital investment in Bioton S.A. preceded Harbin Gloria and Bioton entering into an agreement for the supply and distribution of insulin, which aimed to increase the current level of the commercialization of Bioton’s products on Asian markets.

The Warsaw lawyers from the corporate law and capital markets practices were involved in the provision of comprehensive legal advice. The team was managed by Michał Fereniec, partner, with Adam Puchalski (associate) responsible for issues related to capital markets law and Piotr Smolarczyk (associate) responsible for corporate matters and the special purpose vehicle.

Mr. Zhu Jiman is the founder and the main shareholder, as well as the Chairman of the Supervisory Board and the President of Harbin Gloria Pharmaceuticals Ltd. with its registered office in China. Harbin Gloria, one of the leading pharmaceutical companies on the Chinese market, has in recent years undergone a dynamic expansion through organic growth and multiple acquisitions.